• A Canadian company has a new oral product in the U.S. market
• Second line therapy to competitor
• Patient compliance challenges due to multi-dose daily regimen and side
effects
• Payer challenges stem from reliance on competitor
• Dedicated patient service coordinators for each patient
• Open communication between patient, HCP, pharmacy and EVERSANA
pharmacist
• Consistent follow-ups with HCPs and payers to provide adequate clinical
information for insurance and medication approval
• Onboarding time decreases from 25 to 10 days
• Patient loyalty increases
• 95% patient compliance
• 100% patient satisfaction
• Onboarding time decreases from 25 to 10 days
• Patient loyalty increases
• 95% patient compliance
• 100% patient satisfaction